## 4 Conclusions  
In this study, a mouse model of dorsal bilateral excisional wound healing confirmed the capacity of Ca-alignate-PEGMA hydrogels to store, transport, and release TGF-\(\beta\) neutralizing antibodies at the site of a wound. Macroscopic assessment of the treated wounds revealed that wound sizes did not vary significantly between groups, and there was no evidence of papule, hemorrhage, or necrosis. Erythema surrounding each wound was also similar across all groups. Macroscopic epithelialization and inflammation were also assessed, revealing significantly reduced inflammation scores following application of all CAPH-1D11 treatments, while epithelialization significantly increased followed treatment with CAPH-1D11-10 and CAPH-1D11-50. The observations also supported a concomitant inhibition of fibrotic factors, such as collagen deposition and fibroblast to myofibroblast transition. Overall, these findings suggest that Ca-alignate-PEGMA hydrogels possess sufficient mechanical strength for the topical delivery of therapeutics. However, further studies are needed to explore the impact of Ca-alignate-PEGMA hydrogels loaded with anti-TGF-\(\beta\) antibodies on wound healing long-term. Conceptualization, A.B.C.-C. and A.F.L.-N.; methodology, A.F.L.-N., T.C.-V., P.H.L.-F., A.B.C.-C., N.E.D.-M., R.E. and E.P.-C.; formal analysis, J.G.-B., T.C.-V., R.E. and P.H.L.-F.; investigation, J.G.-B., T.C.-V., P.H.L.-F., A.B.C.-C., N.E.D.-M., R.E. and E.P.-C.; resources, A.F.L.-N., A.B.C.-C., N.E.D.-M., and E.P.-C.; writing--original draft preparation, J.G.-B. ; writing--review and editing, T.C.-V., P.H.L.-F., A.B.C.-C. and A.F.L.-N.; supervision, A.F.L.-N.; project administration, A.F.L.-N.; funding acquisition, A.F.L.-N. All authors have read and agreed to the published version of the manuscript. This research received no external funding. This research received no external funding. The study was conduct according to the guidelines of the Care and Use of Laboratory Animals of the Center for Research and Assistance in Technology and Design of the State of Jalisco, A.C. (CIATE)) and approved by the Institutional Animal Care and Use Committee (CICUAL) with number 2019-020A, in accordance with Mexican regulations \"Technical specifications for production, care and use of laboratory animals\" (NOM-062-ZOO-1999). [PERSON] was supported by a CONACYT scholarship (No. 462358). Professional editing and proofreading were performed by [PERSON]; [PERSON] for figure editing. The authors declare no conflict of interest. References References  
* [1] [PERSON]; [PERSON]; [PERSON]; [PERSON] Transforming growth factor beta1 (TGFbeta1) in physiology and pathology. _Endokynol. Pol._**2013**, _64_, 384-396. [CrossRef] [PubMed]
* [2] [PERSON] [PERSON]; [PERSON]; [PERSON]; [PERSON] [PERSON] Critical Role of Transforming Growth Factor Beta in Different Phases of Wound Healing. _Adv. Wound Care_**2013**, \(2\), 215-224. [CrossRef] [PubMed]
* [3] [PERSON]; [PERSON]; [PERSON] Transforming growth factor beta (TGF-\(\beta\)) isoforms in wound healing and fibrosis. _Wound Repair Regen._**2016**, _24_, 215-222. [CrossRef] [PubMed]
* [4] [PERSON]; [PERSON]; [PERSON] Signalling by transforming growth factor beta isoforms in wound healing and tissue regeneration. _J. Dev. Biol._**2016**, \(4\), 21. [CrossRef]
* [5] [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON] Transforming Growth Factor Beta 3 Is Required for Excisional Wound Repair In Vivo. _PLoS ONE_**2012**, \(7\), e48040. [CrossRef]
* [6] [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]. Discovery and development of averomin (recombinant human transforming growth factor beta 3): A new class of prophylactic therapeutic for the improvement of scarring. _Wound Repair Regen._**2011**, _19_, 38-s48. [CrossRef]
* [7] [PERSON]; [PERSON]; [PERSON] Transforming Growth Factor Beta Signaling in Cutaneous Wound Healing: Lessons Learned from Animal Studies. _Adv. Wound Care_**2013**, \(2\), 225-237.